JP2021525509A5 - - Google Patents
Info
- Publication number
- JP2021525509A5 JP2021525509A5 JP2020566230A JP2020566230A JP2021525509A5 JP 2021525509 A5 JP2021525509 A5 JP 2021525509A5 JP 2020566230 A JP2020566230 A JP 2020566230A JP 2020566230 A JP2020566230 A JP 2020566230A JP 2021525509 A5 JP2021525509 A5 JP 2021525509A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- antigen
- protein
- cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024039934A JP2024073564A (ja) | 2018-06-01 | 2024-03-14 | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679741P | 2018-06-01 | 2018-06-01 | |
| US62/679,741 | 2018-06-01 | ||
| PCT/US2019/035096 WO2019232503A1 (en) | 2018-06-01 | 2019-06-01 | Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024039934A Division JP2024073564A (ja) | 2018-06-01 | 2024-03-14 | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525509A JP2021525509A (ja) | 2021-09-27 |
| JP2021525509A5 true JP2021525509A5 (cg-RX-API-DMAC7.html) | 2022-06-07 |
| JP7599205B2 JP7599205B2 (ja) | 2024-12-13 |
Family
ID=68697132
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566230A Active JP7599205B2 (ja) | 2018-06-01 | 2019-06-01 | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 |
| JP2024039934A Pending JP2024073564A (ja) | 2018-06-01 | 2024-03-14 | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024039934A Pending JP2024073564A (ja) | 2018-06-01 | 2024-03-14 | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 |
Country Status (16)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2991091T3 (es) * | 2017-06-05 | 2024-12-02 | Univ Mie | Proteína de unión a antígeno que reconoce el péptido derivado de MAGE-A4 |
| BR112020005938A2 (pt) | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
| CN116836297A (zh) | 2018-04-12 | 2023-10-03 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| CR20210326A (es) | 2018-12-21 | 2021-09-10 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor |
| EP3733707A1 (en) * | 2019-04-30 | 2020-11-04 | Celyad S.A. | Car t-cells targeting bcma and uses thereof |
| CN114828861A (zh) * | 2019-10-10 | 2022-07-29 | 亚利桑那州立大学董事会 | 表达多特异性免疫细胞接合器的溶瘤病毒 |
| EP3842461A1 (en) * | 2019-12-23 | 2021-06-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
| BR112022013445A2 (pt) * | 2020-01-08 | 2022-09-13 | Univ Texas | Método de modificação de células exterminadoras naturais para direcionar tumores cd70-positivos |
| WO2021188599A1 (en) | 2020-03-16 | 2021-09-23 | University Of Southern California | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| IL297147B1 (en) * | 2020-04-10 | 2026-05-01 | Juno Therapeutics Inc | Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen |
| JP7809068B2 (ja) * | 2020-04-24 | 2026-01-30 | メモリアル スローン ケタリング キャンサー センター | Cd19を標的とするキメラ抗原受容体およびその使用 |
| TW202208412A (zh) * | 2020-05-06 | 2022-03-01 | 瑞士商Crispr治療公司 | 對酪胺酸蛋白激酶樣7(ptk7)特異的經掩蔽的嵌合抗原受體和表現其的免疫細胞 |
| WO2021231237A2 (en) * | 2020-05-11 | 2021-11-18 | Augmenta Bioworks, Inc. | Antibodies for sars-cov-2 and uses thereof |
| US20230357384A1 (en) * | 2020-06-18 | 2023-11-09 | Nextcure, Inc. | Compositions and methods for modulating flrt3 mediated signal transduction |
| JP7765457B2 (ja) * | 2020-08-06 | 2025-11-06 | ステレクシス セラピューティクス,エルエルシー | Il-8抗体及びその使用方法 |
| CN115210262B (zh) * | 2020-09-29 | 2023-07-14 | 昆明赛诺制药股份有限公司 | 人源化抗-cd22重组免疫毒素及其应用 |
| AU2021393434A1 (en) * | 2020-12-02 | 2023-06-22 | Shanghai AbelZeta Ltd. | Bcma-targeted chimeric antigen receptors |
| WO2022170126A2 (en) * | 2021-02-05 | 2022-08-11 | Adagio Therapeutics, Inc. | Compounds specific to coronavirus s protein and uses thereof |
| CA3212006A1 (en) * | 2021-02-26 | 2022-09-01 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
| CN115491358B (zh) * | 2021-06-17 | 2024-09-06 | 复星凯特生物科技有限公司 | 一种靶向b7-h3和folr1双打靶点car t的制备及应用 |
| TW202330594A (zh) * | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ror1結合タンパク質を発現する細胞を培養する方法 |
| CN114106199B (zh) * | 2021-11-19 | 2022-07-12 | 广州百暨基因科技有限公司 | 靶向adgre2的嵌合抗原受体及其应用 |
| WO2023147784A1 (zh) * | 2022-02-07 | 2023-08-10 | 江苏恒瑞医药股份有限公司 | 特异性结合psma和cd3的抗原结合分子及其医药用途 |
| IL315307A (en) * | 2022-03-07 | 2024-10-01 | Medimmune Llc | Treatment methods using CTLA-4 and PD-1 bispecific antibodies |
| WO2023175069A1 (en) * | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Tcr constant region pairing library for pramevld tcrs |
| US20250197848A1 (en) * | 2022-03-16 | 2025-06-19 | Medigene Immuno Therapies Gmbh | Tcr constant region pairing library |
| GB202208119D0 (en) * | 2022-06-01 | 2022-07-13 | Univ Oslo Hf | Anti-steap1 car |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024136899A1 (en) * | 2022-12-21 | 2024-06-27 | Synthorx, Inc. | Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies |
| GB202301421D0 (en) * | 2023-02-01 | 2023-03-15 | Univ Oslo Hf | Switch receptor for use in adoptive cell therapy |
| PE20260290A1 (es) | 2023-03-31 | 2026-02-10 | Abelzeta Inc | Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma |
| WO2024220834A1 (en) * | 2023-04-19 | 2024-10-24 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car-t cells co-expressing cd40l |
| WO2024243093A2 (en) * | 2023-05-19 | 2024-11-28 | The Regents Of The University Of California | Multispecific antibodies targeting cd3 and cd22 |
| EP4784626A1 (en) | 2023-09-25 | 2026-08-05 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
| IL327310A (en) | 2023-09-25 | 2026-05-01 | Kelonia Therapeutics Inc | Cancer treatment vehicles |
| WO2025151607A1 (en) * | 2024-01-10 | 2025-07-17 | Santa Ana Bio, Inc. | Methods and compositions for treating autoimmune, allergic and inflammatory diseases |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| WO2025245381A1 (en) | 2024-05-23 | 2025-11-27 | The Trustrees Of Dartmouth College | Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues |
| WO2025257781A1 (en) * | 2024-06-14 | 2025-12-18 | Novartis Ag | Treatment of systemic sclerosis using anti-baff-r antibodies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
| GB9809658D0 (en) * | 1998-05-06 | 1998-07-01 | Celltech Therapeutics Ltd | Biological products |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| CA2531118C (en) | 2003-07-01 | 2013-01-08 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
| EP2389443B1 (en) * | 2009-01-23 | 2018-11-14 | Roger Williams Hospital | Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| EP3459560B1 (en) | 2011-04-08 | 2021-02-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| US9833476B2 (en) * | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| WO2013059343A1 (en) | 2011-10-17 | 2013-04-25 | Massachusetts Institute Of Technology | Intracellular delivery |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| DK2971045T3 (da) | 2013-03-13 | 2019-09-16 | Health Research Inc | Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen |
| ES2959480T3 (es) | 2014-02-07 | 2024-02-26 | Univ Mcmaster | Acoplador de células T - antígeno trifuncional y métodos y usos del mismo |
| EP3131927B8 (en) * | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| AU2015292744C1 (en) * | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| WO2016174852A1 (ja) * | 2015-04-30 | 2016-11-03 | 株式会社デンソー | 蒸発器 |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| TWI833684B (zh) * | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| MX2018004721A (es) * | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| US20190112380A1 (en) * | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| AU2017240233B2 (en) | 2016-03-31 | 2022-07-14 | University Of Southern California | A highly sensitive and specific luciferase based reporter assay for antigen detection |
| CN109416147B (zh) | 2016-06-30 | 2021-12-21 | 伊利诺斯工具制品有限公司 | 作为设备控制台的硬连线平板电脑/智能电话的固持器 |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| BR112020005938A2 (pt) | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
-
2019
- 2019-06-01 JP JP2020566230A patent/JP7599205B2/ja active Active
- 2019-06-01 EP EP19811044.7A patent/EP3802822A4/en active Pending
- 2019-06-01 BR BR112020024246-2A patent/BR112020024246A2/pt unknown
- 2019-06-01 WO PCT/US2019/035096 patent/WO2019232503A1/en not_active Ceased
- 2019-06-01 IL IL279100A patent/IL279100B2/en unknown
- 2019-06-01 IL IL317990A patent/IL317990A/en unknown
- 2019-06-01 SG SG11202011837UA patent/SG11202011837UA/en unknown
- 2019-06-01 AU AU2019279084A patent/AU2019279084B2/en active Active
- 2019-06-01 MX MX2020012927A patent/MX2020012927A/es unknown
- 2019-06-01 CN CN201980049331.5A patent/CN113286879B/zh active Active
- 2019-06-01 US US15/734,203 patent/US20210137977A1/en active Pending
- 2019-06-01 CA CA3101510A patent/CA3101510A1/en active Pending
- 2019-06-01 EA EA202092945A patent/EA202092945A1/ru unknown
- 2019-06-01 KR KR1020207038038A patent/KR20210057705A/ko not_active Ceased
- 2019-06-03 TW TW108119201A patent/TW202018083A/zh unknown
-
2020
- 2020-11-26 ZA ZA2020/07393A patent/ZA202007393B/en unknown
- 2020-11-27 MX MX2026004393A patent/MX2026004393A/es unknown
- 2020-12-29 CO CONC2020/0016586A patent/CO2020016586A2/es unknown
-
2022
- 2022-05-23 ZA ZA2022/05644A patent/ZA202205644B/en unknown
-
2024
- 2024-03-14 JP JP2024039934A patent/JP2024073564A/ja active Pending
-
2025
- 2025-07-16 AU AU2025205493A patent/AU2025205493A1/en active Pending